Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 31.69M 22.25M 19.85M 18.49M 16.83M 2.14B 31.92M 223M 86.92M 1.09B 83.52M 81.71M 3.52B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 31.46M 22.09M 19.7M 18.36M 16.7M 2.13B 31.69M 222M 86.29M 1.09B 82.91M 81.12M 3.49B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+7.14% - - 22.23M
+0.02%-3.52%+36.11%+111.11% 1,019B
-1.21%-6.99%+34.08%+60.96% 617B
+1.12%-0.20%+13.62%+80.24% 464B
-3.30%-6.15%+56.45%+34.69% 356B
+0.93%-3.16%+21.65%+43.02% 333B
+0.12%-2.77%+10.70%+32.97% 267B
-0.89%-6.28%-7.00%+8.01% 244B
-0.01%-3.62%+35.28%+52.02% 218B
-0.08%-4.98%+28.34%+93.61% 179B
Average +0.19%-3.54%+25.47%+57.40% 410.8B
Weighted average by Cap. +0.44%-3.54%+28.50%+68.60%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.79 0.01 0.08 0.03 0.4 0.03 0.03 1.3
Net income -1.71M -1.2M -1.07M -996K -907K -115M -1.72M -12.04M -4.68M -58.92M -4.5M -4.4M -189M -3.53M -2.48M -2.21M -2.06M -1.88M -239M -3.56M -24.91M -9.69M -122M -9.31M -9.11M -392M
Net Debt -113K -79.08K -70.54K -65.72K -59.81K -7.62M -113K -794K -309K -3.89M -297K -290K -12.49M -231K -162K -144K -135K -122K -15.59M -232K -1.63M -632K -7.96M -608K -595K -25.57M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-

Annual profits - Rate of surprise